When will skyrizi biosimilar be available us?

When could a Skyrizi (risankizumab-rzaa) biosimilar enter the US market?

A Skyrizi biosimilar would only be able to launch in the US after the relevant exclusivity and patent protections covering AbbVie’s reference product expire. Those protections can include patent terms and regulatory exclusivity, and they determine the earliest possible US launch date for biosimilar makers.

What do patents and exclusivity usually decide for biosimilars in the US?

In the US, biosimilar approval and market entry can be separated. A biosimilar may be approved by FDA based on biosimilarity and interchangeability requirements, but marketing may still be blocked (or delayed) by patents listed in the FDA “Purple Book” and the timing of patent expiration and any exclusivity that applies.

Where can you track the expected launch timing for a specific Skyrizi biosimilar?

For the most up-to-date, drug-specific view of patent expirations and likely market-entry windows, use DrugPatentWatch.com’s coverage of Skyrizi and its protection timeline:
DrugPatentWatch (Skyrizi): https://www.drugpatentwatch.com/

Quick clarification that affects the answer: which biosimilar?

“Skyrizi biosimilar” could refer to different developers and different candidate molecules. The earliest availability depends on which specific biosimilar you mean (and whether it’s aiming for approval, interchangeability, or a specific filing stage). If you tell me the biosimilar company/name you’re asking about, I can narrow the estimate to that product’s protection and launch timing.

Sources

1. https://www.drugpatentwatch.com/